Plasma levels of fibrinolytic proteins and the risk of venous thrombosis

被引：0
|
作者：
Meltzer, M. E. [1 ,2 ]
Lisman, T. [2 ,3 ]
Meijers, J. C. M. [4 ]
de Groot, P. G. [2 ]
Doggen, C. J. M. [5 ]
Rosendaal, F. R. [6 ]
机构：
[1] Leiden Univ, Clin Epidemiol, Med Ctr, Leiden, Netherlands
[2] Univ Med Ctr Utrecht, Clin Chem & Hematol, Utrecht, Netherlands
[3] Univ Med Ctr Groningen, Dept Surg, Surg Res Lab, Groningen, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Vasc Med & Expt Vasc Med, Amsterdam, Netherlands
[5] Leiden Univ, Clin Epidemiol, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands
[6] Leiden Univ, Clin Epidemiol Thrombosis & Hemostasis, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OC-WE-016
引用
收藏
页码：207 / 207
页数：1
相关论文
共 50 条
  • [41] FIBRINOLYTIC THERAPY FOR VENOUS THROMBOSIS WITH STREPTOKINASE, UROKINASE AND ACTIVATOR
    SCHENK, H
    PILGER, E
    GYPSER, G
    ELSINGER, A
    SAILER, S
    BLUT, 1980, 40 (01): : 55 - 55
  • [42] Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels
    Morange, P. -E.
    Saut, N.
    Antoni, G.
    Emmerich, J.
    Tregouet, D. -A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) : 229 - 231
  • [43] Identification of polymorphisms in the TAFI gene promoter:: Relationship with plasma TAFI levels and risk of venous thrombosis.
    Franco, RF
    Fagundes, MG
    Meijers, JCM
    Reitsma, PH
    Lourenço, DM
    Morelli, VM
    Maffei, FH
    Piccinato, CE
    Silva, WA
    Zago, MA
    BLOOD, 2000, 96 (11) : 565A - +
  • [44] F11 Gene Duplication Causes Elevated FXI Plasma Levels and Is a Risk for Venous Thrombosis
    Van Laer, Christine
    Peerlinck, Kathelijne
    Jacquemin, Marc
    Thys, Chantal
    Downes, Kate
    Labarque, Veerle
    Freson, Kathleen
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (06) : 1058 - 1060
  • [45] Elevated plasma factor VIII levels in patients with venous thrombosis - Constitutional risk factor or secondary epiphenomenon?
    Ryan, Kevin
    O'Donnell, James S.
    THROMBOSIS RESEARCH, 2012, 129 (02) : 105 - 106
  • [46] IMPAIRED FIBRINOLYTIC ACTIVITY IN PATIENTS WITH SUPERFICIAL VENOUS THROMBOSIS
    Spirkoska, Ana
    Jezovnik, Mateja Kaja
    Poredos, Pavel
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (09) : E372 - E372
  • [47] TREATMENT OF ACUTE DEEP VENOUS THROMBOSIS WITH FIBRINOLYTIC AGENTS
    PERSSON, AV
    EKDAHL, KM
    MEDICAL CLINICS OF NORTH AMERICA, 1986, 70 (06) : 1325 - 1332
  • [48] FIBRINOLYTIC THERAPY WITH STREPTOKINASE AND UROKINASE IN DEEP VENOUS THROMBOSIS
    TRUBESTEIN, G
    WILGALIS, M
    LUDWIG, M
    BRECHT, T
    CHRIST, F
    VASA-JOURNAL OF VASCULAR DISEASES, 1986, : 11 - 11
  • [49] IMPAIRED FIBRINOLYTIC CAPACITY PREDISPOSES FOR RECURRENCE OF VENOUS THROMBOSIS
    KORNINGER, C
    LECHNER, K
    NIESSNER, H
    GOSSINGER, H
    KUNDI, M
    THROMBOSIS AND HAEMOSTASIS, 1984, 52 (02) : 127 - 130
  • [50] Low protein Z levels and the risk of venous thrombosis.
    Martinelli, I
    Battaglioli, T
    Razzari, C
    Biguzzi, E
    Mannucci, PM
    BLOOD, 2005, 106 (11) : 467A - 467A
12345